Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth

{
  "signal_id": "37750f64-3071-eb67-7379-a838dc663f79",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-21T17:00:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/21/3365777/0/en/psoriatic-arthritis-market-landscape-6-key-late-stage-drugs-set-to-drive-future-growth-delveinsight.html",
    "title": "Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight",
    "excerpt": "The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies. The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies.",
    "product": "ICOTYDE",
    "summary": "Johnson & Johnson's emerging therapy, ICOTYDE (icotrokinra), is expected to significantly reshape the Psoriatic Arthritis (PsA) market.",
    "planning": false,
    "confidence": 0.8,
    "product_data": {
      "name": "ICOTYDE",
      "full_text": "ICOTYDE (icotrokinra; Johnson & Johnson)",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-21T17:00:00Z",
    "article_sentence": "The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inadequate responses to existing therapies."
  }
}

curl https://signals.autobound.ai/v1/signals/37750f64-3071-eb67-7379-a838dc663f79 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'